ABL Diagnostics Strengthens Strategic Supplier Agreements to Support Accelerated Growth

The renewed and expanded agreements provide improved commercial conditions, including more competitive pricing, optimized contractual terms, and enhanced supply security. These improvements will ...

ABL Diagnostics Update Regarding Non-Binding Letter of Intent

ABL Diagnostics S.A. (Euronext: ABLD – ISIN: FR001400AHX6) informs the market that the non-binding Letter of Intent entered into between ProPhase Labs, Inc. and Advanced Biological Laboratories S.A. ( ...

ABL Diagnostics and CDL Pharma secure a multi year renewal of clinical services with a long standing Pharma partner

The multi‑year renewal strengthens ABL’s integrated platform, improving revenue visibility and supporting the Group’s ...
News Medical on MSN

IFN-γ identified as a powerful blood biomarker for Alzheimer’s

By Dr. Priyom Bose, Ph.D. A new study uncovers interferon gamma as both a powerful blood-based signal of Alzheimer’s disease ( AD ) and a potential mechanistic bridge between genetic risk and damaging ...

All Invest Securities Flash Update to the Equity Research Coverage of ABL Diagnostics (For Professional Investors)

Strong Buy reiterated with a €8.37 target price following the 21 January 2026 Flash; last close on 22 January 2026: ...